healthcare

Pfizer logo

Pfizer Faces Reality Check With Earnings

Pfizer Inc. (NYSE: PFE) reported its fourth-quarter results Tuesday before the markets open as $0.54 in earnings per share (EPS) and $13.1 billion in revenue. That compared to Thomson Reuters ...
Read Full Story »
Shake Shack IPO

Shake Shack Leads the Parade of IPOs Scheduled for Next Week

Initial public offerings (IPO) were a bit slow getting off the mark in 2015, but the week of January 26 looks ready to make up for the tepid start. A ...
Read Full Story »
down market

Has eHealth Fallen Too Far?

eHealth Inc. (NASDAQ: EHTH) was devastated in Thursday’s trading as the company announced its preliminary results for its fourth quarter. This appears to be a company that went from being ...
Read Full Story »
health care

Did Ziopharm and Intrexon Run Too Much on an MD Anderson Pact?

When two stocks run up over 50% and 30% on the same news, investors have to wonder if the move in the stock was justified or if the news-pop was ...
Read Full Story »
DNA

Has Agenus Run Too Much?

Agenus Inc. (NASDAQ: AGEN), in conjunction with Incyte Corp. (NASDAQ: INCY), announced a global license for the development and commercialization of Agenus’s proprietary Retrocyte Display antibody discovery platform. As a ...
Read Full Story »
surgeons

The Bullish and Bearish Case for UnitedHealth in 2015

Now that the bull market is nearing its sixth year, investors have to wonder about valuations after exponential gains from the March 2009 bottom. 2014 brought gains of 7.5% in ...
Read Full Story »
Money background. Close-up.

Gilead Continues to Recover from Express Scripts Loss

After the markets closed on Thursday, Gilead Sciences Inc. (NASDAQ: GILD) was picked up by Anthem Inc. (NYSE: ANTM) to provide its hepatitis C drug as the primary option for ...
Read Full Story »
merck

The Bullish and Bearish Case for Merck in 2015

The bull market is almost six years old, and the market gains in 2014 took the Dow Jones Industrial Average up 7.5% and the S&P 500 Index up 11.4%. While ...
Read Full Story »
Johnson & Johnson Logo

The Bullish and Bearish Case for Johnson & Johnson in 2015

The bull market is almost six years old now, and the Dow Jones Industrial Average rose by 7.5% and the S&P 500 Index rose 11.4% in 2014. While those index ...
Read Full Story »
Money background. Close-up.

Is Immunomedics Worth 50% More?

Immunomedics Inc. (NASDAQ: IMMU) announced Tuesday morning that it had appointed a new chief medical officer (CMO). As a result, Wells Fargo issued an analyst call implying a massive upside ...
Read Full Story »
Pills

Analyst’s 8 Top Health Care Stocks for 2015

Health care had an outstanding year in 2014. In fact the sector through last Friday was up 23.30%, which placed it third in the S&P 500 sector race, just behind ...
Read Full Story »
Pills

Is a Generic Diovan for You?

Many investors have to worry about the so-called patent cliff in pharmaceutical companies. Generic launches are often priced into most analyst estimates, but these generic launches are always important to ...
Read Full Story »
Rite Aid

Rite Aid Scores New Street-High Analyst Price Target

Rite Aid Corp. (NYSE: RAD) is a turnaround stock that keeps getting attention. The pharmacy and drug store player now has a new street-high analyst target price. Credit Suisse reiterated ...
Read Full Story »
knees

Flex Pharma Files for IPO

Flex Pharma Inc. has filed with the Securities and Exchange Commission (SEC) for its initial public offering (IPO). No terms were given, but the filing is valued up to $60 ...
Read Full Story »
thumbs up

Is Gilead Already Coming Back Into Favor?

Over the past year, Gilead Sciences Inc. (NASDAQ: GILD) has been a top dog with regards to hepatitis C treatments, pulling in over $6.2 billion in sales for these treatments ...
Read Full Story »